Physician
Hematology
Yogenthiran Saunthararajah, MB BCH
|
|
Give Review
Yogenthiran Saunthararajah, MB BCH works in the field of Hematology. He over the years received 1 awards: "CMS Meaningful Use Stage 1 Certification". Yogenthiran Saunthararajah, MB BCH has written publications. He has 73 publications published with PubMed. The lastest paper is: 'Impact of vancomycin-resistant enterococcal bacteremia on outcome during acute myeloid leukemia induction therapy.' He is registered with Medicare and accepts Medicare payments.
Publications
- Impact of vancomycin-resistant enterococcal bacteremia on outcome during Acute myeloid leukemia induction therapy.
- Distinct iron architecture in SF3B1 mutant Myelodysplastic syndromes patients is linked to an SLC25A37 splice variant with a retained intron.
- Sex difference in Myelodysplastic syndrome survival and balance in randomized clinical trials.
- Sex differences in the incidence of chronic myeloid Leukemia.
- Ribosomal S6 Kinase and AKT Phosphorylation as Pharmacodynamic Biomarkers in Patients With Myelodysplastic Syndrome Treated With RAD001.
- Key clinical observations after 5-azacytidine and decitabine treatment of Myelodysplastic syndromes suggest practical solutions for better outcomes.
- dNTP Supply Gene Expression Patterns after P53 Loss.
- Predictive Factors for Latency Period and a Prognostic Model for Survival in Patients with Therapy-related AML.
- Somatic SETBP1 mutations in Myeloid malignancies.
- Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet syndrome that was refractory to 5-azacitidine.
- Gender, cytidine deaminase, and 5-aza/decitabine--response.
- Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in Myeloid malignancies.
- AML Cells are differentially sensitive to chemotherapy treatment in a human xenograft model.
- Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine...
- High cytidine deaminase expression in the liver provides sanctuary for Cancer cells from decitabine treatment effects.
- SF3B1 haploinsufficiency leads to formation of ring sideroblasts in Myelodysplastic syndromes.
- Expression of phosphorylated signal transducer and activator of transcription 5 is associated with an increased risk of death in Acute myeloid leukemia.
- Differential effects of low-dose decitabine on Immune effector and suppressor responses in melanoma-bearing mice.
- Monosomy 3 by FISH in uveal melanoma: variability in techniques and results.
- Effect of AGM and fetal liver-derived stromal Cell lines on globin expression in adult baboon (P. anubis) bone marrow-derived erythroid progenitors.
- Chromosome 3 status in uveal melanoma: a comparison of fluorescence in Situ hybridization and single-nucleotide polymorphism array.
- CEBPE activation in PML-RARA Cells by arsenic.
- Polycomb segment Myeloid malignancies.
- Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of Oral decitabine.
- CpG methylation patterns and decitabine treatment response in Acute myeloid leukemia cells and normal hematopoietic precursors.
- p53-Independent, Normal Stem Cell Sparing Epigenetic Differentiation Therapy for Myeloid and Other Malignancies.
- p53 independent epigenetic-differentiation treatment in xenotransplant models of Acute myeloid leukemia.
- A pilot study of subcutaneous decitabine in β-thalassemia intermedia.
- RUNX1 regulates corepressor interactions of PU.1.
- Standard clinical practice underestimates the role and significance of erythropoietin deficiency in Sickle cell disease.
- Race and intensity of post-remission therapy in Acute myeloid leukemia.
- Noncytotoxic differentiation treatment of renal cell Cancer.
- Circulating tumor Cells in uveal melanoma.
- A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed Acute myeloid leukemia.
- S110, a novel decitabine dinucleotide, increases fetal hemoglobin levels in baboons (P. anubis).
- Novel homo- and hemizygous mutations in EZH2 in Myeloid malignancies.
- Decitabine maintains hematopoietic precursor self-renewal by preventing repression of stem Cell genes by a differentiation-inducing stimulus.
- Patient-reported outcomes: descriptors of nociceptive and neuropathic pain and barriers to effective pain management in adult outpatients with Sickle cell disease.
- Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.
- Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?
- Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell Anemia.
- Clinical effectiveness of decitabine in severe Sickle cell disease.
- DNA methylation and mechanism of action of 5-azacytidine.
- Oral decitabine reactivates expression of the methylated gamma-globin gene in Papio anubis.
- Decitabine and Sickle cell disease: molecular therapy for a molecular disease.
- Differentiation impairment and the evolution of MDS.
- RUNX1-RUNX1 homodimerization modulates RUNX1 activity and function.
- Higher numbers of blood CD14+ cells before starting conditioning regimen correlate with greater risk of Acute graft-versus-host disease in allogeneic stem cell transpl...
- Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem Cell tr...
- Prolonged responses after autologous stem cell transplantation in African-American patients with multiple Myeloma.
- Normal and transforming functions of RUNX1: a perspective.
- Combinatorial action of RUNX1 and PU.1 in the regulation of hematopoiesis.
- Clinical studies with fetal hemoglobin-enhancing agents in Sickle cell disease.
- EVI1 induces Myelodysplastic syndrome in mice.
- DNA hypo-methylating agents and Sickle cell disease.
- AML1-ETO decreases ETO-2 (MTG16) interactions with nuclear receptor corepressor, an effect that impairs granulocyte differentiation.
- Pathologic quiz case: a 68-year-old man with thrombocytosis and ringed sideroblasts. Essential thrombocythemia with ringed sideroblasts.
- Modification of hematopoietic stem Cell fate by 5aza 2'deoxycytidine and trichostatin A.
- Acute graft-versus-host disease and steroid treatment impair CD11c+ and CD123+ dendritic cell reconstitution after allogeneic peripheral blood stem cell transplantation.
- Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with Sickle cell disease.
- HLA-DR4 predicts haematological response to cyclosporine in T-large granular lymphocyte lymphoproliferative Disorders.
- A simple method to predict response to immunosuppressive therapy in patients with Myelodysplastic syndrome.
- Effect of hydroxyurea on mortality and morbidity in adult sickle cell Anemia: risks and benefits up to 9 years of treatment.
- HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic Anemia and predicts a response to immunosuppression in myelodysplastic syndrome.
- Antithymocyte globulin for treatment of the bone marrow failure associated with Myelodysplastic syndromes.
- Contribution of gastrin-releasing peptide and its receptor to villus development in the murine and human gastrointestinal tract.
- Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic Anemia syndrome.
- Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoImmune process.
- Advances in experimental treatment of beta-thalassaemia.
- Coincident Myelodysplastic syndrome and T-cell large granular lymphocytic disease: clinical and pathophysiological features.
- Myelodysplastic syndrome and aplastic Anemia: distinct entities or diseases linked by a common pathophysiology?
- Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO Leukemia cells.
Schools
University Of Wales School Of Medicine
University Hawaii
NIH
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Bladder Cancer
- Carcinoma in Situ
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
National Institutes of Health Clinical Center -
University of Hawaii
Drug Facts
| NPI NUMBER | 1184737637 | |
| NPPES Provider LastName | SAUNTHARARAJAH | |
| NPPES Provider FirstName | YOGENTHIRAN | |
| NPPES Provider ZIPCode | 441950001 | |
| NPPES Provider State | OH | |
| Specialty Description | Hematology | |
| Total Claim Count | 85.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1184737637 |
| Last Name Of The Provider | SAUNTHARARAJAH |
| First Name Of The Provider | YOGENTHIRAN |
| View All |
Similar Doctors
|
|
Dr. Joan E. Trey, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dale H. Cowan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anita Schwandt, MD |
|
Dr. Clark W. Distelhorst, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Ila Tamaskar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rami Manochakian, MD |
|
Dr. Joseph A. Bokar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark Cooper, MD |
|
|
Dr. Kristine A. Nelson, MD |
|
|
Dr. Michelle E. Treasure, MD |
|
|
Dr. Ann Tan, MD
This Doctor is OpenDoctor Recommended.
|